Axogen Inc vs JPMorgan Equity Premium Income ETF — how do they compare? Axogen Inc trades at $38.89 (market cap $2.06B), while JPMorgan Equity Premium Income ETF trades at $56.66. The key difference: Axogen Inc is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AXGN | JEPI | |
|---|---|---|
Market Cap | $2.06B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $46.19 | $59.88 |
52-Week Low | $11.28 | $55.29 |
Enterprise Value | $1.98B | — |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
JEPI trades at $56.76 with no price change, showing stability amid mixed technical signals. The ETF maintains a bullish technical outlook with strong moving average support, though oscillators suggest neutral momentum. Recent dividend payments of $0.39 and $0.45 demonstrate its income-focused strategy, while financial media highlights its 8%+ yield and covered call approach as key attractions for income investors.
JEPI's covered call strategy provides consistent income but limits upside potential during bull markets. The ETF faces competition from alternatives like SPYI and tax efficiency concerns, though its active management offers drawdown protection. Current technical strength supports near-term stability, but investors should weigh income benefits against capped returns in rising markets.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →